Can an arthritis drug stop lung cancer in former smokers?
NCT ID NCT06038526
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests whether canakinumab, a drug that blocks inflammation, can lower certain proteins linked to cancer growth in former smokers at high risk. About 41 participants will provide cheek, nose, and blood samples before and after treatment. The goal is to see if the drug changes inflammation markers, not to cure or treat cancer directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIGARETTE SMOKING-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could spot cancers that standard scans overlook
- Nicotine pouches vs. patches: can they help appalachian smokers quit cigarettes and cut cancer risk?
- Can a conversation aid empower lung cancer patients?
- Can couples coping together ease the burden of advanced cancer?
- Can a custom toolkit help indigenous smokers spot lung cancer earlier?
- Eye movements may reveal nicotine addiction in vapers